CBT After Esketamine Cuts Relapse Risk, Trial Finds

What the Study Found

A newly published randomized controlled trial called CBT-ENDURE, appearing in the Journal of Clinical Psychiatry, offers an important answer to a question clinicians have been wrestling with since esketamine (brand name Spravato) earned FDA approval: what happens after the acute treatment phase ends?

The trial enrolled patients with major depressive disorder who also had active suicidal ideation — one of the most clinically urgent and difficult-to-treat presentations in psychiatry. After an initial course of esketamine nasal spray, participants were randomized to either continue with standard care or complete a structured 16-week course of Cognitive Behavioral Therapy (CBT). Researchers then tracked outcomes including suicidal ideation severity and overall depression scores.

The result was clear: patients who received CBT following esketamine showed significantly greater reductions in both suicidal ideation and depression severity compared to those who received esketamine alone. The differences weren't marginal — they were clinically meaningful, suggesting that CBT isn't just a nice complement to ketamine-based treatment but may be a necessary one for sustaining its benefits.

Why This Matters: The Durability Problem

Anyone who has researched ketamine or esketamine treatment quickly encounters a consistent theme: the rapid onset of relief is remarkable, but that relief doesn't always last. Both IV ketamine and intranasal esketamine can produce dramatic reductions in depression and suicidal thinking within hours to days — a speed that no traditional antidepressant can match. But maintaining those gains over weeks and months has proven more challenging, and relapse after a course of treatment is a real concern.

This is the "durability problem," and it's one of the most active areas of research in ketamine medicine. Clinics and researchers have explored various strategies: maintenance dosing schedules, combining ketamine with oral antidepressants, and now — as CBT-ENDURE demonstrates — pairing it with structured psychotherapy.

The rationale for CBT as a follow-up makes intuitive sense. Ketamine appears to open a window of neuroplasticity — a period during which the brain is more receptive to change and learning. CBT, which systematically works to identify and restructure negative thought patterns, may be ideally suited to capitalize on that window. In other words, esketamine might make the brain more ready to absorb the skills that CBT teaches, while CBT provides the scaffolding to sustain the improvements esketamine initiates.

The CBT-ENDURE trial gives that hypothesis meaningful empirical backing, at least for patients dealing with suicidal ideation alongside depression — a group for whom relapse carries particularly high stakes.

Esketamine vs. IV Ketamine: Does This Apply to Both?

It's worth noting that this trial specifically studied esketamine — the FDA-approved nasal spray formulation (Spravato) delivered in certified healthcare settings. Esketamine and IV racemic ketamine are related but not identical treatments, and research on one doesn't automatically transfer to the other. That said, the underlying mechanism — rapid antidepressant action followed by a potential neuroplastic window — is thought to be similar across ketamine formulations. Many practitioners who offer IV ketamine already encourage or require patients to engage in therapy alongside treatment, and CBT-ENDURE provides fresh data supporting that instinct.

If you're evaluating IV ketamine clinics or ketamine-assisted therapy programs, it's reasonable to ask how they approach the period after acute treatment ends. A clinic that simply administers infusions without a plan for psychological support or maintenance may be leaving significant value on the table.

For esketamine patients specifically, this research reinforces that Spravato is most effective as part of a broader treatment plan — not a standalone fix. The FDA already requires esketamine to be administered in a certified clinical setting with observation, but there's no mandated psychotherapy component. CBT-ENDURE suggests there probably should be, particularly for patients with suicidal ideation.

Practical Implications for Patients Comparing Options

For readers weighing ketamine treatment options, this study offers a few concrete considerations.

Look for integrated care models. The most effective ketamine treatment may not be the one that offers the most infusions or the most competitive pricing — it may be the one that pairs the pharmacological treatment with a structured therapeutic framework. Ketamine-assisted psychotherapy (KAP) programs, which explicitly combine altered states with therapeutic sessions, are built on this principle. CBT-ENDURE extends that logic to post-treatment care even when the therapy isn't administered simultaneously.

Plan for what comes after. It's easy to focus entirely on the acute treatment phase when researching ketamine, but the post-treatment period deserves equal attention. If a provider doesn't have a clear answer for what happens after your final session or infusion — how you'll maintain progress, whether follow-up therapy is part of the plan, what triggers a return to treatment — that's worth pressing on.

Suicidal ideation requires the highest standard of care. The CBT-ENDURE population included people with active suicidal ideation, and the benefits of combined treatment were measured against that backdrop. If suicidal thinking is part of your picture, this study underscores the importance of choosing a provider who treats the whole clinical scenario, not just the depressive episode in isolation. Esketamine's rapid effect on suicidal ideation has been one of its most compelling clinical features; CBT-ENDURE suggests that effect can be meaningfully extended with the right follow-up.

The full trial is published in the Journal of Clinical Psychiatry and is available here. As this research continues to evolve, it reinforces a growing consensus in the field: ketamine opens a door, but therapy helps people walk through it and stay on the other side.